Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.
The Japanese drugmaker JP:4503 said it would fund the planned acquisition with about 800 billion yen of bank loans and commercial papers, in addition to existing cash on hand, and that it expected to repay new debt within the next five to seven years.
Astellas…
Read the full article here
